Research goal
Covers compounds researched for their effects on sleep onset, slow-wave sleep depth, and circadian rhythm regulation, primarily through GH axis and pineal pathways.
| Compound | Class | Primary Mechanism | Commonly Reported For | Link |
|---|---|---|---|---|
| Ipamorelin | GHRP / Ghrelin mimetic | Stimulates nocturnal GH pulse; modest sleep quality improvement | GH release, sleep quality, recovery | View profile → |
| MK-677 | GH secretagogue (non-peptide) | Oral ghrelin mimetic; pronounced slow-wave sleep increase; sustained GH | Deep sleep, GH/IGF-1 elevation | Profile coming soon |
| Epitalon | Tetrapeptide / epigenetic regulator | Normalises pineal melatonin production; circadian rhythm regulation | Sleep regulation, melatonin, circadian health | View profile → |
The relationship between growth hormone secretion and sleep architecture is well characterised in the endocrinological literature. The majority of endogenous GH release in healthy adults occurs during the first episode of slow-wave sleep (SWS), driven by hypothalamic growth hormone-releasing hormone (GHRH) activity and modulated by somatostatin inhibition. GH secretagogues — compounds that mimic ghrelin or potentiate GHRH signalling — amplify this nocturnal GH pulse and have been associated with downstream improvements in slow-wave sleep architecture. This bidirectional relationship, in which GH release promotes SWS and SWS in turn promotes GH release, creates a positive feedback axis that GHRPs and GH secretagogues may augment. Research has investigated this axis as a target for age-related sleep quality decline, as both SWS depth and nocturnal GH amplitude decrease substantially across the lifespan.
MK-677 (Ibutamoren) represents the most extensively published compound in this context with respect to polysomnographic data. A randomised trial published by Copinschi et al. in 1997 demonstrated significant increases in REM sleep duration and slow-wave sleep time in healthy young and elderly subjects following MK-677 administration. Subsequent studies documented sustained GH and IGF-1 elevation alongside sleep architecture improvements. The oral bioavailability and extended half-life of MK-677 — properties absent from injectable peptide GHRPs — make it particularly tractable as a research tool for studying the GH-sleep interface over extended periods, though these same pharmacokinetic properties also raise questions about continuous GH axis stimulation in non-GH-deficient populations.
Epitalon engages sleep biology through a distinct mechanism: the pineal gland. The pineal gland produces melatonin in a circadian-gated pattern, and its secretory function declines with age in a manner that correlates with disrupted sleep architecture and circadian rhythm fragmentation in elderly populations. Research has investigated Epitalon for its potential role in normalising pineal melatonin secretion, with Khavinson-group studies reporting restoration of melatonin rhythms in aged animals and elderly human cohorts following Epitalon administration. Unlike exogenous melatonin supplementation, which provides pharmacological replacement of the hormone, Epitalon's proposed mechanism involves upregulation of endogenous pineal production — a distinction relevant to physiological rhythm restoration rather than simple hormone replacement.
Ipamorelin is a pentapeptide growth hormone-releasing peptide (GHRP) notable within its class for high selectivity — it stimulates GH release with minimal co-secretion of cortisol or prolactin at research doses, an advantage over earlier GHRPs such as GHRP-2 and GHRP-6. Research has investigated Ipamorelin for its potential role in amplifying the nocturnal GH pulse when administered at or before sleep onset, with consequent mild improvements in sleep quality reported in anecdotal accounts. Its sleep benefit is considered modest relative to MK-677 in the anecdotal literature, but its tolerability profile and absence of significant cortisol stimulation are often cited as advantages for longer-term research contexts. Commonly reported doses range from 100 to 300 micrograms administered subcutaneously in the evening.
MK-677 (Ibutamoren) is an orally active, non-peptide ghrelin receptor agonist developed by Merck with a half-life of approximately 24 hours, producing sustained elevation of GH and IGF-1. It is the most clinically investigated GH secretagogue for sleep-specific endpoints, with polysomnographic data demonstrating significant increases in slow-wave sleep duration and REM sleep in both young and elderly subjects. Research has investigated MK-677 for its potential role in GH-deficiency states, muscle wasting conditions, and age-related sleep deterioration. The oral route and once-daily dosing distinguish it from injectable GHRP peptides, and commonly reported doses in research trial contexts range from 10 to 25 mg orally at bedtime. Reported side effects in research and anecdotal accounts include increased appetite, water retention, and transient elevations in fasting blood glucose.
Epitalon's relevance to sleep research derives from its origin as a synthetic analogue of epithalamin, a natural pineal gland extract, and its reported capacity to restore melatonin secretory rhythms in aging individuals with diminished pineal function. Research has investigated Epitalon for its potential role in normalising the amplitude and timing of melatonin peaks in elderly cohorts, with the Khavinson research program reporting improved sleep quality indices alongside circadian rhythm restoration in human subjects. In contrast to GH secretagogue compounds, Epitalon does not directly modulate the GH axis; its sleep-relevant mechanism is pineal-melatonergic rather than somatotropic. Commonly reported protocols in research contexts involve cyclical administration, with doses ranging from 5 to 10 mg per cycle administered subcutaneously or intranasally.
No established stack protocols documented for this goal at this time.
Why do GH secretagogues improve sleep quality?
GH secretagogues improve sleep quality primarily by amplifying the nocturnal GH pulse that occurs during slow-wave sleep. The relationship between GH and SWS is bidirectional: SWS creates the neurochemical conditions for hypothalamic GHRH release, which drives pituitary GH secretion, and GH in turn has sleep-promoting and sleep-deepening properties mediated partly through its effects on hypothalamic GHRH and somatostatin balance. Compounds that act as ghrelin receptor agonists — including Ipamorelin and MK-677 — synergise with endogenous GHRH signalling to enhance this nocturnal GH peak, which results in increased SWS duration measurable by polysomnography. The mechanism is particularly relevant in older individuals, in whom both SWS and nocturnal GH secretion decline in parallel.
How does MK-677 compare to Ipamorelin for sleep specifically?
MK-677 produces a substantially more pronounced and well-documented sleep effect than Ipamorelin in the available literature. Polysomnographic studies have directly measured SWS and REM increases with MK-677, providing objective evidence of sleep architecture change rather than subjective report alone. Ipamorelin's sleep benefits are reported primarily in anecdotal accounts and are considered secondary to its primary GH-releasing function; no published polysomnographic trials for Ipamorelin and sleep architecture exist as of this reference. Practically, MK-677 is oral with a long half-life, enabling once-nightly dosing with sustained GH elevation, while Ipamorelin requires subcutaneous injection with a short half-life requiring pre-sleep timing. Researchers interested specifically in slow-wave sleep improvement will find substantially more data supporting MK-677 as an investigational tool for this endpoint.
What is Epitalon's specific mechanism of action for sleep?
Epitalon's mechanism for sleep is routed through the pineal gland rather than the GH axis. As a synthetic tetrapeptide derived from the natural pineal extract epithalamin, Epitalon has been shown in research by the Khavinson group to stimulate pinealocyte activity and restore the age-related decline in melatonin synthesis and secretion. Melatonin is the primary circadian timing signal in mammals, with its nocturnal rise driving sleep onset and its circadian patterning coordinating peripheral tissue rhythms. In aged individuals whose pineal function has declined, Epitalon is hypothesised to restore melatonin secretory amplitude toward younger physiological norms, improving both sleep onset and circadian rhythm coherence. This is mechanistically distinct from GH secretagogue approaches and positions Epitalon as a circadian regulator rather than a sleep-architecture modifier in the strict polysomnographic sense.
Are these compounds typically used at night, and why?
Yes — all three compounds on this page are reported in research and anecdotal contexts as evening or pre-sleep administrations, for mechanistic reasons specific to each. Ipamorelin and MK-677 are timed to coincide with the natural nocturnal GH secretory window; administration before sleep onset allows the GH secretagogue effect to amplify the first SWS-associated GH pulse rather than producing a GH release during waking hours when somatostatin tone tends to be higher. Epitalon's pineal mechanism similarly aligns with evening administration, as pinealocyte melatonin synthesis is gated to darkness and the pre-sleep period; stimulating pineal activity during daylight hours would be physiologically discordant with the circadian rhythm Epitalon is intended to restore. Evening timing for these compounds therefore reflects genuine pharmacological rationale rather than convention.